Kangabio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $15M

  • Investors
  • 4

Kangabio General Information

Description

Researcher and developer of drugs intend to serve the pharmaceutical industry. The company is mainly focused on the research and development of clinical drug discovery and includes innovative prodrug molecules for immune agonists and multispecific antibodies, providing clients with potential treatment with less toxicity.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 8
  • Number 151 Libing Road, Pudong New Area
  • Shanghai, 201203
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Building 8
  • Number 151 Libing Road, Pudong New Area
  • Shanghai, 201203
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kangabio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 01-Dec-2025 $15M Completed Generating Revenue
1. Early Stage VC 26-Jun-2022 Completed Generating Revenue
To view Kangabio’s complete valuation and funding history, request access »

Kangabio Patents

Kangabio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026201125-A1 T cell engager antibody Pending 28-Mar-2025
JP-2026514090-A Multifunctional molecule containing shielding interleukin 12 and method of use Pending 12-Apr-2023
AU-2024251934-A1 Multifunctional molecules comprising masked interleukin 12 and methods of use Pending 12-Apr-2023
EP-4695282-A1 Multifunctional molecules comprising masked interleukin 12 and methods of use Pending 12-Apr-2023
WO-2024212827-A1 Multifunctional molecules comprising masked interleukin 12 and methods of use Inactive 12-Apr-2023 C07K14/5434
To view Kangabio’s complete patent history, request access »

Kangabio Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
BOHE Angel Fund Venture Capital Minority
Daoyuan Capital Venture Capital Minority
Taikun Fund Venture Capital Minority
Teda VC Venture Capital Minority
To view Kangabio’s complete investors history, request access »

Kangabio FAQs

  • When was Kangabio founded?

    Kangabio was founded in 2021.

  • Where is Kangabio headquartered?

    Kangabio is headquartered in Shanghai, China.

  • What industry is Kangabio in?

    Kangabio’s primary industry is Drug Discovery.

  • Is Kangabio a private or public company?

    Kangabio is a Private company.

  • What is Kangabio’s current revenue?

    The current revenue for Kangabio is .

  • How much funding has Kangabio raised over time?

    Kangabio has raised $29.9M.

  • Who are Kangabio’s investors?

    BOHE Angel Fund, Daoyuan Capital, Taikun Fund, and Teda VC have invested in Kangabio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process